In recent years, an increasing number of studies have focused on discovering TRPV1 antagonists and agonists/desensitizers as therapeutic solutions for chronic, neuropathic and inflammatory pain, but also for migraine and cluster headache [8,19,60]. The gene discussed is TRPV1; the disease is Cluster headache.